Johnson & Johnson, a global leader in eye health, announced today that its TECNIS PureSee™ purely refractive intraocular lens (IOL) for individuals with presbyopia is now available in India. The TECNIS PureSee™ IOL features a purely refractive design that delivers uninterrupted, high-quality, vision with high best-in-category contrast and low-light performance, comparable to a monofocal IOL.

全球眼科保健领导者强生公司今天宣布，其专为老花眼患者设计的TECNIS PureSee™纯折射人工晶状体 (IOL) 现已在印度上市。TECNIS PureSee™ IOL 采用纯折射设计，可提供不间断的高质量视觉，具有同类最佳的对比度和低光性能，可与单焦点 IOL 媲美。

“Cataract surgery is the most common surgery performed globally, with 28 million procedures each year. But only 10-15% of patients are getting advanced optical IOLs specifically designed for addressing issues of astigmatism and presbyopia, said Burzin Shahana, Country Manager, Surgical Vision India & South Asia, Johnson & Johnson MedTech. “We’re proud to launch the TECNIS PureSee™ IOL, giving surgeons and a growing number of patients in India the choice of a premium IOL that combines clarity of vision and reduced visual symptoms.”

“白内障手术是全球最常见的手术，每年有 2800 万例。但只有 10-15% 的患者获得了专门为解决散光和老花眼问题而设计的先进光学 IOL，”强生医疗科技印度和南亚外科视觉区域经理 Burzin Shahana 表示。“我们很自豪地推出 TECNIS PureSee™ IOL，让印度外科医生和越来越多的患者可以选择一款兼具清晰视力和减少视觉症状的优质 IOL。”

While choosing any IOL, surgeons and patients have to consider many factors. For example, a lens that offers clear sight at all distances without spectacles, may not be able to remove glares and halos. The purely refractive design of TECNIS PureSee™ lens addresses these issues and therefore improves the overall outcomes for both patients and surgeons.

在选择任何 IOL 时，外科医生和患者都必须考虑许多因素。例如，无需戴眼镜即可在任何距离提供清晰视力的晶状体可能无法消除眩光和光晕。TECNIS PureSee™晶状体的纯折射设计解决了这些问题，因此改善了患者和外科医生的整体治疗效果。

With its purely refractive design, the TECNIS PureSee™ IOL ensures surgeons’ ease of use in providing high tolerance to refractive error. The TECNIS PureSee™ IOL offers important benefits, including: Uninterrupted high-quality vision, with excellent distance and intermediate vision, as well as functional near vision for increased spectacle independence. A dysphotopsia profile that is comparable to a monofocal IOL in frequency, bothersome and difficulty levels, which means little to no visual symptoms, such as halos, glares, and starbursts. By 2050, the number of people aged over 60 years old is expected to more than double to 2.1 billion, and Asia Pacific will account for 65% of the global increase for this age group. Cataracts are the leading cause of treatable blindness in the world. Medical science and technology have advanced today such that a qualified eye surgeon can remove a cataract and replace it with an IOL, and patients typically experience improved eye sight the very same day. The TECNIS PureSee™ IOL is now available in India.

TECNIS PureSee™ IOL采用纯屈光设计，可确保外科医生轻松使用，对屈光不正具有较高的耐受性。TECNIS PureSee™ IOL 具有重要优势，包括： 不间断的高质量视觉，具有出色的远距离和中距离视觉以及功能性近距离视觉，可提高对眼镜的独立性。 视觉障碍的情况在发生频率、困扰程度和难度上与单焦点 IOL 相当，这意味着几乎没有视觉症状，如光晕、眩光和星芒。 到 2050 年，60 岁以上的人口数量预计将增加一倍以上，达到 21 亿，亚太地区将占全球该年龄段人口增长的 65%。白内障是全球可治愈失明的主要原因。如今，医学科学和技术已经非常先进，合格的眼科医生可以摘除白内障并用人工晶状体替换，患者通常当天就能看到视力改善。 TECNIS PureSee™ IOL 现已在印度上市。